Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study.

UNLABELLED We conducted a prospective, multicenter, double-blinded, dose-ranging study to compare the risk/benefit ratio of large- and small-dose aprotinin with placebo after major orthopedic surgery. Fifty-eight patients were randomized into three groups: Large-Dose Aprotinin (4 M kallikrein inactivator unit [KIU] bolus before surgery followed by a continuous infusion of 1 M KIU/h until the end of surgery), Small-Dose Aprotinin (2 M KIU bolus plus 0.5 M KIU/h), and Placebo. Bleeding was measured and calculated. Bilateral ascending venography was systematically performed on the third postoperative day. Measured and calculated blood loss decreased in the Large-Dose Aprotinin group (calculated bleeding, whole blood, hematocrit 30%, median [range], 2,023 mL [633-4,113] as compared with placebo, 3,577 mL [1,670-21,758 mL]). The total number of homologous and autologous units was also significantly decreased in the Large-Dose Aprotinin group (2 U [0-5 U] as compared with placebo, 4 U [0-42 U]). No increase in deep vein thrombosis or pulmonary embolism was observed in the aprotinin groups. Large-dose aprotinin was safe and effective in dramatically reducing the measured and calculated bleeding and the amount of transfused red blood cell units after major orthopedic surgery. IMPLICATIONS Large doses of aprotinin decrease blood loss and transfusion amount in major orthopedic surgery.

[1]  D. Raines,et al.  Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. , 2001, Anesthesia and analgesia.

[2]  C. Colwell,et al.  Prevention of venous thromboembolism. , 1994, Chest.

[3]  C. Samama,et al.  Structure, Pharmacology, and Clinical Use of Antifibrinolytic Agents , 2001 .

[4]  R. Hall,et al.  Aprotinin Decreases Exposure to Allogeneic Blood During Primary Unilateral Total Hip Replacement* , 2000, The Journal of bone and joint surgery. American volume.

[5]  L. Lindgren,et al.  Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study , 2000, The Lancet.

[6]  J. Rütt,et al.  A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. , 1998, European journal of anaesthesiology.

[7]  B. Chaitman,et al.  Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. , 1998, The Journal of thoracic and cardiovascular surgery.

[8]  W. Dietrich,et al.  Incidence of hypersensitivity reactions. , 1998, The Annals of thoracic surgery.

[9]  X. Capdevila,et al.  Aprotinin Decreases Blood Loss and Homologous Transfusions in Patients Undergoing Major Orthopedic Surgery , 1998, Anesthesiology.

[10]  M. McCarroll,et al.  The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. , 1996, Journal of clinical anesthesia.

[11]  F. Mercuriali,et al.  Proposal of an algorithm to help the choice of the best transfusion strategy. , 1996, Current medical research and opinion.

[12]  M. Abel,et al.  Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. , 1995, Anesthesia and analgesia.

[13]  R. Bourne,et al.  Aprotinin Decreases Blood Loss in Patients Undergoing Revision or Bilateral Total Hip Arthroplasty , 1995, Anesthesia and analgesia.

[14]  C. Samama,et al.  Aprotinin to decrease bleeding and intraoperative blood transfusion requirements during descending thoracic and thoracoabdominal aortic aneurysmectomy using cardiopulmonary bypass , 1994, Annals of vascular surgery.

[15]  J. Levy,et al.  Pharmacokinetics of Aprotinin in Preoperative Cardiac Surgical Patients , 1994, Anesthesiology.

[16]  M. Lamy,et al.  High‐dose Aprotinin Reduces Blood Loss in Patients Undergoing Total Hip Replacement Surgery , 1994, Anesthesiology.

[17]  J. Haberer,et al.  Anaphylactic reaction to aprotinin during cardiac surgery , 1993, Anaesthesia.

[18]  T. Feeley,et al.  Use of aprotinin to reduce intraoperative bleeding. , 1993, The Western journal of medicine.

[19]  S. Bélisle,et al.  Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients , 1993, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[20]  F. Loop,et al.  Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.

[21]  J. Griffin,et al.  Aprotinin (trasylol) is a competitive inhibitor of activated protein C. , 1989, Thrombosis research.

[22]  K. M. Taylor,et al.  EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.